These are very exciting times for dermatology. Basic research is being applied to the development of new and more effective biologics to treat some of the most challenging conditions, psoriasis among them.
FDA Approves Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Definitions and Diagnostic Criteria of Generalized Pustular Psoriasis Require Continuity, Accuracy, Researchers Report
Comparing Devices to Assess Facial Pigmentary and Inflammatory Conditions